Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease

Biochemical Pharmacology

Volumn 56, Issue 8, 1998, Pages 921-933

  McNaught, K St P ^a   Carrupt, P A ^a   Altomare, C ^a   Cellamare, S ^a   Carotti, A ^a   Testa, B ^a   Jenner, P ^a   Marsden, C D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

1,2,3,4 tetrahydroisoquinoline; 1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); 1 methyl 4 phenylpyridinium (MPP+); Isoquinoline derivatives; Neurotoxin; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; FREE RADICAL; ISOQUINOLINE DERIVATIVE; NEUROTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL DEATH; DOPAMINERGIC NERVE CELL; MARMOSET; MITOCHONDRIAL RESPIRATION; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

EID: 0031693023     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00142-7     Document Type: Article

References (92)

1. S. Forno Pathology of Parkinson’s disease C.D. Marsden S. Fahn Movement Disorders, Neurology 2 1981 Butterworth Scientific London 21 40
2. Agid Y, Javoy-Agid F and Ruberg M, Biochemistry of neurotransmitters in Parkinson’s disease. In: Movement Disorders (Eds. Marsden CD and Fahn S), Vol. 2, pp. 166–230. Butterworth & Co. Publishers, Stoneham, MA, 1987.
3. P. Jenner A.H.V. Schapira C.D. Marsden New insights into the cause of Parkinson’s disease Neurology 42 1992 2241 2250
4. G.B. Steventon M.T.E. Heafield R.H. Waring A.C. Williams Xenobiotic metabolism in Parkinson’s disease Neurology 39 1989 883 887
5. O. Bandmann J. Vaughan P. Holmans C.D. Marsden N.W. Wood Association of slow acetylator genotype for N -acteyltransferase 2 with familial Parkinson’s disease Lancet 350 1997 1136 1139
6. D.T. Dexter A. Carayon F. Javoy-Agid Y. Agid F.R. Wells S.E. Daniel P. Jenner C.D. Marsden Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia Brain 114 1991 1953 1975
7. H. Saggu J. Cooksey D. Dexter F.R. Wells A. Lees P. Jenner C.D. Marsden A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra J Neurochem 53 1989 692 697
8. J. Sian D.T. Dexter A.J. Lees S. Daniel Y. Agid F. Javoy-Agid P. Jenner C.D. Marsden Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia Ann Neurol 36 1994 348 355
9. J. Sian D.T. Dexter A.J. Lees S. Daniel P. Jenner C.D. Marsden Glutathione-related enzymes in brain in Parkinson’s disease Ann Neurol 36 1994 356 361
10. D.T. Dexter A.E. Holley W.D. Flitter T.F. Slater R.F. Wells S.E. Daniel A.J. Lees P. Jenner C.D. Marsden Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra An HPLC and ESR study Mov Disord 9 1994 92 97
11. J.R. Sanchez-Ramos E. Overvik B.N. Ames A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum in Parkinson’s disease brain Neurodegeneration 3 1994 197 204
12. 1 reductase (complex I) deficiency in Parkinson’s disease J Neurochem 55 1990 2142 2145
13. Y. Mizuno S. Matuda H. Yoshino H. Mori N. Hattori S. Ikebe An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson’s disease Ann Neurol 35 1994 204 210
14. Tanner CM, Epidemiological clues to the cause of Parkinson’s disease. In: Movement Disorders (Eds. Marsden CD and Fahn S), Vol. 3, pp. 124–144. Butterworth-Heinemann Ltd., Oxford, U.K., 1994.
15. J.W. Langston I. Irwin G.A. Ricaurte Neurotoxins, parkinsonism and Parkinson’s disease Pharmacol Ther 32 1987 19 49
16. R.T. Ross Drug-induced parkinsonism and other movement disorders Can J Neurol Sci 17 1990 155 162
17. J.W. Langston P. Ballard J.W. Tetrud I. Irwin Chronic parkinsonism in humans due to a product of meperidine-analogue synthesis Science 219 1983 979 980
18. I. Irwin J.W. Langston MPTP and Parkinson’s disease A.L. Harvey Natural and Synthetic Neurotoxins 1993 Academic Press New York 225 256
19. K. Chiba A.J. Trevor N. Castagnoli Jr Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase Biochem Biophys Res Commun 120 1984 574 578
20. J.A. Javitch R.J. D’Amato S.M. Strittmatter S.H. Snyder Parkinsonism inducing neurotoxin N -methyl-4-phenyl-1,2,3,6-tetrahydropyridine Uptake of the metabolite N -methyl-4-phenylpyridine by dopamine neurons explains selective toxicity Proc Natl Acad Sci USA 82 1985 2173 2177
21. R.R. Ramsay T.P. Singer Energy-dependent uptake of N -methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria J Biol Chem 261 1986 7585 7587
22. +) cause rapid ATP depletion in isolated hepatocytes Biochem Biophys Res Commun 137 1986 310 315
23. Y. Mizuno T. Saitoh N. Sone Inhibition of mitochondrial α-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion Biochem Biophys Res Commun 143 1987 971 976
24. M.J.W. Cleeter J.M. Cooper A.H.V. Schapira Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium Evidence for free radical involvement J Neurochem 58 1992 786 789
25. +) in the pathogenesis of Parkinson’s disease Brain Res 575 1993 285 298
26. T. Nagatsu Isoquinoline neurotoxins in the brain and Parkinson’s disease Neurosci Res 29 1997 99 111
27. T. Nagatsu M. Yoshida An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions Neurosci Lett 87 1987 178 182
28. R. Deitrich V. Erwin Biogenic amine-aldehyde condensation products Tetrahydroisoquinolines and tryptolines (β-carbolines) Annu Rev Pharmacol Toxicol 20 1980 55 80
29. H. Rommelspacher T. May R. Susilo β-Carbolines and tetrahydroisoquinolines Detection and function in mammals Planta Med 57 Suppl 1991 S85 S92
30. Holmstedt B, Betacarbolines and tetrahydroisoquinolines: Historical and ethnopharmacological background. In: Progress in Clinical and Biological Research (Eds. Bloom F, Barchas J, Sandler M and Usdin E), Vol. 90, pp. 3–13. Alan R. Liss, New York, 1982.
31. Rommelspacher H and Susilo R, Tetrahydroisoquinolines and β-carbolines: Putative natural substances in plants and mammals. In: Progress in Drug Research (Eds. Herausgegeben V and Jucker E), Vol. 29, pp. 415–459. Birkhäuser, Basel, 1985.
32. T. Niwa H. Yoshizumo A. Tatematsu S. Matsuura T. Nagatsu Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods J Chromatogr 493 1989 347 352
33. Y. Makino S. Ohta O. Tachikawa M. Hirobe Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in foods Compounds related to Parkinson’s disease Life Sci 43 1988 373 378
34. M. Kohno S. Ohta M. Hirobe Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain Biochem Biophys Res Commun 140 1986 448 454
35. S. Ohta M. Kohno Y. Makino O. Tachikawa M. Hirobe Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline are present in the human brain Relation to Parkinson’s disease Biomed Res 8 1987 453 456
36. T. Niwa N. Nakeda H. Yoshizumi A. Tatematsu M. Yoshida P. Dostert M. Naoi T. Nagatsu Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains Biochem Biophys Res Commun 177 1991 603 609
37. T. Niwa N. Takeda Y. Hashizume T. Nagatsu Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroisoquinoline in parkinsonian and normal human brains Biochem Biophys Res Commun 144 1989 1084 1089
38. W. Maruyama D. Nakahara M. Ota T. Takahashi A. Takahashi T. Nagatsu M. Naoi N-Methylation of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, ( R )-salsolinol, in rat brains In vivo microdialysis study J Neurochem 59 1992 395 400
39. W. Maruyama G. Sobue K. Matsubara Y. Hashizume P. Dostert M. Naoi A dopaminergic neurotoxin, 1( R ),2( N )-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N -methyl( R )salsolinol, and its oxidation product, 1,2( N )-dimethyl-6,7-dihydroxyisoquinolinium ion, accumulate in the nigro-striatal system of the human brain Neurosci Lett 223 1997 61 64
40. M. Naoi S. Matsurra H. Parvez T. Takahashi Y. Hirata M. Minami T. Nagatsu Oxidation of N -methyl-1,2,3,4-tetrahydroisoquinoline into the N -methyl-isoquinolinium ion by monoamine oxidase J Neurochem 52 1989 653 655
41. M. Naoi S. Matsuura T. Takahashi T. Nagatsu A N -methyltransferase in human brain catalyses N -methylation of 1,2,3,4-tetrahydroisoquinoline into N -methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N -methylisoquinolinium ion Biochem Biophys Res Commun 161 1989 1213 1219
42. T. Niwa N. Takeda A. Tatematsu S. Matsuura M. Yoshida T. Nagatsu Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as provided by gas chromatography–mass spectrometry J Chromatogr 452 1988 85 91
43. K. Kikuchi Y. Nagatsu Y. Makino T. Mashino S. Ohta M. Hirobe Metabolism and penetration through the blood–brain barrier of parkinsonism-related compounds 1,2,3,4-tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline Drug Metab Dispos 19 1991 257 262
44. H. Kawai Y. Makino M. Hirobe S. Ohta Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives Uptake by dopamine transporter and activity to induce parkinsonism J Neurochem 70 1998 745 751
45. Y. Kotake Y. Tasaki Y. Makino S. Ohta M. Hirobe 1-Benzyl-1,2,3,4-tetrahydoisoquinoline as a parkinsonism-inducing agent A novel endogenous amine in mouse and parkinsonian CSF J Neurochem 65 1995 2633 2638
46. Y. Kotake M. Yoshida M. Ogawa Y. Tasaki M. Hirobe S. Ohta Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate Neurosci Lett 217 1996 69 71
47. T. Suzuki S. Fujita S. Narimatsu Y. Masubuchi M. Tachibana S. Ohta M. Hirobe Cytochrome P450 isoenzymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes FASEB J 6 1992 771 776
48. R.D. Myers Isoquinolines, beta-carbolines and alcohol drinking Involvement of opioid and dopaminergic mechanisms Experientia 45 1989 436 443
49. U. Thull S. Kneubuhler P. Gaillard P.-A. Carrupt B. Testa C. Altomare A. Carotti P. Jenner K.St.P. McNaught Inhibition of monoamine oxidase by isoquinoline derivatives Biochem Pharmacol 50 1995 869 877
50. K. Suzuki Y. Mizuno M. Yoshida Selective inhibition of complex I of the brain electron transport system by tetrahydroisoquinoline Biochem Biophys Res Commun 162 1989 1541 1545
51. K. Suzuki Y. Mizuno Y. Yasuhiro T. Nagatsu Y. Mitsuo Selective inhibition of complex I by N -methylisoquinolinium ion and N -methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain J Neurol Sci 109 1992 219 223
52. K.St.P. McNaught C. Altomare S. Cellamare A. Carotti U. Thull P.A. Carrupt B. Testa P. Jenner C.D. Marsden Inhibition of α-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Neuroreport 6 1995 1105 1108
53. K.St.P. McNaught U. Thull P.A. Carrupt C. Altomare S. Cellamare A. Carotti B. Testa P. Jenner C.D. Marsden Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Biochem Pharmacol 50 1995 1903 1911
54. N. Morikawa Y. Nakagawa-Hattori Y. Mizuno Effect of dopamine, dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial respiration and complex I activity J Neurochem 66 1996 1174 1181
55. D.J. Horgan T.P. Singer J. Cassida Studies on the respiratory chain-linked reduced nicotinamide adenine dinucleotide dehydrogenase J Biol Chem 243 1968 834 843
56. +) against mitochondria of mouse brain J Neurol Sci 86 1988 97 110
57. +), the neurotoxic metabolite of MPTP Biochem Biophys Res Commun 148 1987 684 693
58. M.R. Gluck S.K. Youngster R.R. Ramsay T.P. Singer W.J. Nicklas Studies on the characterization of the inhibitory mechanism of 4′-alkylated 1-methyl-4-phenylpyridinium and phenylpyridine analogues in mitochondria and electron transport particles J Neurochem 63 1994 655 661
59. M.R. Gluck M.J. Krueger R.R. Ramsay S.O. Sablin T.P. Singer W.J. Nicklas Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations J Biol Chem 269 1994 3167 3174
60. R.R. Ramsay J.I. Salach J. Dadgar T.P. Singer Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism Biochem Biophys Res Commun 135 1986 269 275
61. K. Suzuki Y. Mizuno M. Yoshida Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain Neurochem Res 7 1990 705 710
62. L.M. Sayre F. Wang P.K. Arora N.J. Riachi S.I. Harik C.L. Hoppel Dopaminergic neurotoxicity in vivo and inhibition of mitochondrial respiration in vitro by possible endogenous pyridinium-like substances J Neurochem 57 1991 2106 2115
63. K.St.P. McNaught U. Thull P.A. Carrupt C. Altomare S. Cellamare A. Carotti B. Testa P. Jenner C.D. Marsden Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on mitochondrial respiration Biochem Pharmacol 51 1996 1503 1511
64. T.A. Seaton J.M. Cooper A.H.V. Schapira Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors Brain Res 777 1997 110 118
65. W. Maruyama P. Dostert K. Matsubara M. Naoi N-Methyl( R )salsolinol produces hydroxyl radicals Involvement in neurotoxicity Free Radic Biol Med 19 1995 67 75
66. W. Maruyama W. Dostert M. Naoi Dopamine-derived 1-methyl-6,7-dihydroxyisoquinoline as hydroxy radical promoters and scavengers In vivo and in vitro studies J Neurochem 64 1995 2635 2643
67. W. Maruyama M. Naoi T. Kasamatsu Y. Hashizume T. Takahashi K. Kohda P. Dostert An endogenous dopaminergic neurotoxin, N -methyl-( R )-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells J Neurochem 69 1997 322 329
68. J.C. Davila P. Davis D. Acosta Changes in glutathione and cellular energy as potential mechanisms of papaverine-induced hepatotoxicity in vitro Toxicol Appl Pharmacol 109 1991 28 36
69. R.E. Heikkila G. Cohen D. Dembiec Tetrahydroisoquinoline alkaloids Uptake by rat brain homogenates and inhibition of catecholamine uptake J Pharmacol Exp Ther 179 1971 250 258
70. Y. Hirata M. Minami M. Naoi T. Nagatsu Studies on the uptake of N -methylisoquinolinium ion into rat striatal slices using high-performance liquid chromatography with fluorimetric detection J Chromatogr 503 1990 189 195
71. J. Liptrot D. Holdup O. Phillipson 1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol depletes catecholamines in rat brain J Neurochem 61 1993 2199 2206
72. 3H]dopamine into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Biochem Pharmacol 52 1996 29 34
73. +) destroys cultured mesencephalic dopamine neurons Biogenic Amines 8 1991 61 67
74. +) and tetrahydroisoquinoline derivatives on dopaminergic neurons in ventral mesencephalic-striatal co-culture Neurodegeneration 3 1994 33 42
75. K. Goto H. Mochizuki T. Hattori N. Nakamura Y. Mizuno Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture Brain Res 754 1997 260 268
76. T. Takahashi W. Maruyama Y. Deng P. Dostert D. Nakahara T. Niwa S. Ohta M. Naoi Cytotoxicity of endogenous isoquinolines to human dopaminergic neuroblastoma SH-SY5Y cells J Neural Transm 104 1997 59 66
77. K.St.P. McNaught U. Thull P.A. Carrupt C. Altomare S. Cellamare A. Carotti B. Testa P. Jenner C.D. Marsden Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neurosci Lett 206 1996 37 40
78. M. Yoshida T. Niwa T. Nagatsu Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline The behavioural and biochemical changes Neurosci Lett 119 1990 109 113
79. Yoshida M, Ogawa M, Suzuki K and Nagatsu T, Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues. In: Advances in Neurology (Eds. Narabayashi H, Nagatsu T, Yanagisawa N and Mizuno Y), Vol. 60, pp. 207–211. Raven Press, New York, 1993.
80. M. Ogawa M. Araki I. Nagatsu T. Nagatsu M. Yoshida The effect of 1,2,3,4-tetrahydroisoquinoline (TIQ) on mesencephalic dopaminergic neurons in C57BL-6J mice Immunohistochemical studies-tyrosine hydroxylase Biogenic Amines 6 1989 427 436
81. T.L. Perry K. Jones S. Hansen Tetrahydroisoquinoline lacks dopaminergic nigrostriatal neurotoxicity in mice Neurosci Lett 85 1988 101 104
82. A. Moser F. Siebecker F. Nobbe V. Bohme Rotational behaviours and neurochemical changes in unilateral N -methyl-norsalsolinol and 6-hydroxydopamine lesioned rats Exp Brain Res 112 1996 89 95
83. T. Origitano J. Hannigan M.A. Collins Rat brain salsolinol and blood–brain barrier Brain Res 224 1981 446 451
84. K.St.P. McNaught U. Thull P.A. Carrupt C. Altomare S. Cellamare A. Carotti B. Testa P. Jenner C.D. Marsden Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neurodegeneration 5 1996 265 274
85. J. Cashaw Determination of tetrahydropapaveroline in the urine of parkinsonian patients receiving l -dopa-carbidopa (Sinemet) therapy by high performance liquid chromatography J Chromatogr 613 1993 267 273
86. Kondo I and Kanazawa I, Debrisoquine hydroxylase and Parkinson’s disease. In: Advances in Neurology (Eds. Narabayashi H, Nagatsu T, Yanagisawa N and Mizuno Y), Vol. 60, pp. 338–342. Raven Press, New York, 1993.
87. Z.X. Zhang G.C. Román Worldwide occurrence of Parkinson’s disease An updated review Neuroepidemiology 12 1993 195 208
88. P. Jenner C.W. Olanow Pathological evidence for oxidative stress in Parkinson’s disease and related degenerative disorders C.W. Olanow P. Jenner M. Youdim Neurodegeneration and Neuroprotection in Parkinson’s Disease 1996 Academic Press London 23 45
89. S. Fahn G. Cohen The oxidant stress hypothesis in Parkinson’s disease Evidence supporting it Ann Neurol 32 1992 804 812
90. L. Antkiewicz-Michaluk A. Krygowska-Wajs A. Szczudlik I. Romanska J. Vetulani Increase in salsolinol in the cerebrospinal fluid of parkinsonian patients is related to dementia Advantage of a new high-performance liquid chromatography methodology Biol Psychiatry 42 1997 514 518
91. A. Zuddas G. Corsini S. Schinelli J.N. Johannessen U. Porzio I.J. Kopin MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra Brain Res 501 1989 1 10
92. + neurotoxicity and delays its elimination from the striatum Brain Res 501 1989 11 22